{"id":"elbasvir-oral-granules","safety":{"commonSideEffects":[{"rate":"10%","effect":"Fatigue"},{"rate":"9%","effect":"Headache"},{"rate":"8%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Elbasvir is a direct-acting antiviral that targets the NS5A protein of hepatitis C virus, preventing viral replication.","oneSentence":"Inhibits NS5A protein of hepatitis C virus","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:36:55.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT03379506","phase":"PHASE2","title":"Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-01-25","conditions":"HCV Infection","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-8742"],"phase":"phase_2","status":"active","brandName":"Elbasvir Oral Granules","genericName":"Elbasvir Oral Granules","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits NS5A protein of hepatitis C virus Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}